TQB2868 not checked

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
2 active
4 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“TQB2868 injection: PD-L1 and Transforming Growth Factor-beta (TGF - β) dual antibody”In the company’s words, NCT07165951 on ClinicalTrials.gov
Tested for
Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Neoplasms
Main trialPhase 3
“This study adopts a randomized, open label, placebo-controlled, multicenter trial design. OS was the primary endpoint, and eligible subjects were randomly divided into 1:1 groups and received TQB2868 injection and anlotinib hydrochloride capsules combined with chemotherapy, compared to placebo combined with chemotherapy.”In the company’s words, NCT07165951 on ClinicalTrials.gov

Other drugs for Metastatic Pancreatic Ductal Adenocarcinoma

All 203 drugs for Metastatic Pancreatic Ductal Adenocarcinoma

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 3Recruiting May 2028 Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Phase 2Recruiting Nov 2026 Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms
Phase 2Withdrawn Feb 2025 A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer
Phase 1Unknown Jun 2023 Clinical Trial of TQB2868 Injection in Subjects With Advanced Malignant Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow TQB2868

Following is part of Solo: you see every change to TQB2868 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in